Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 82)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Acetylcysteine |
Approved, Investigational |
Phase 4 |
|
616-91-1 |
581 12035 |
Synonyms:
(2R)-2-ACETAMIDO-3-SULFANYLPROPANOIC ACID
(2R)-2-Acetylamino-3-sulfanylpropanoate
(2R)-2-Acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulphanylpropanoate
(2R)-2-Acetylamino-3-sulphanylpropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoate
(R)-2-Acetylamino-3-mercaptopropanoic acid
(R)-Mercaptate
(R)-Mercaptic acid
(R)-Mercapturic acid
2-[(1-Hydroxyethylidene)amino]-3-sulfanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoic acid
2-acetylamino-3-mercapto-Propionate
2-acetylamino-3-mercapto-Propionic acid
5052
Ac pharma brand OF acetylcysteine
ACC
ACC-600
Acebraus
Acemuc
Acetabs
Acetadote
Acetilcisteina
Acetylcystein al
Acetylcystein atid
Acetylcystein heumann
Acetylcystein trom
Acetylcystein, mentopin
Acetylcysteine
Acetylcysteine ac-pharma brand
Acetylcysteine alcon brand
Acetylcysteine aluid brand
Acetylcysteine atid brand
Acetylcysteine azupharma brand
Acetylcysteine betapharm brand
Acetylcysteine bioiberica brand
Acetylcysteine bouchara brand
Acetylcysteine centrafarm brand
Acetylcysteine disphar brand
Acetylcysteine farmasan brand
Acetylcysteine fresenius brand
Acetylcysteine génévrier brand
Acétylcystéine GNR
Acetylcysteine GNR-pharma brand
Acetylcysteine guerbet brand
Acetylcysteine hermes brand
Acetylcysteine heumann brand
Acetylcysteine hydrochloride
Acetylcysteine inpharzam brand
Acetylcysteine intra brand
Acetylcysteine klinge brand
Acetylcysteine krewel brand
Acetylcysteine lichtenstein brand
Acetylcysteine lindopharm brand
Acetylcysteine merck brand
Acetylcysteine oberlin brand
Acetylcysteine pfleger brand
Acetylcysteine pharbita brand
Acetylcysteine roberts brand
Acetylcysteine sodium
Acetylcysteine temmler brand
Acetylcysteine teva brand
Acetylcysteine thiemann brand
Acetylcysteine trommsdorff brand
Acetylcysteine upsa brand
Acetylcysteine whitehall brand
Acetylcysteine zambon brand
Acetylcysteine zinc
Acetylcysteine zyma brand
Acetylcysteine, (D)-isomer
Acetylcysteine, (DL)-isomer
Acetylcysteine, monoammonium salt
Acetylcysteine, monosodium salt
Acetylcysteinum
Acetylin
Acetyst
Acid, mercapturic
Ac-pharma brand OF acetylcysteine
A-CYS
Airbron
Alcon brand OF acetylcysteine
Allen and hanburys brand OF acetylcysteine
Aluid brand OF acetylcysteine
Alveolex
Atid brand OF acetylcysteine
Azubronchin
Azupharma brand OF acetylcysteine
Betapharm brand OF acetylcysteine
Bioiberica brand OF acetylcysteine
Bisolvon nac
Boehringer ingelheim brand OF acetylcysteine
Bouchara brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine sodium salt
Bristol-myers squibb brand OF acetylcysteine
Bristol-myers squibb brand OF acetylcysteine sodium salt
Bromuc
broncho Fips
broncho-Fips
BronchoFips
Broncholysin
Broncoclar
Centrafarm brand OF acetylcysteine
CETYLEV
Codotussyl
Cystamucil
dampo Mucopect
|
Dey brand OF acetylcysteine sodium salt
Disphar brand OF acetylcysteine
Durabronchal
EN-CYS
Eurespiran
Exomuc
Fabrol
Farmasan brand OF acetylcysteine
Fluimicil infantil
Fluimucetin
Fluimucil
FLUIMUCIL 600
FLUIMUCIL LONG
FLUIMUCIL N
Flumucetin
Fluprowit
Frekatuss
Fresenius brand OF acetylcysteine
Genac
Génévrier brand OF acetylcysteine
GNR Pharma brand OF acetylcysteine
GNR-Pharma brand OF acetylcysteine
Guerbet brand OF acetylcysteine
Hermes brand OF acetylcysteine
Heumann brand OF acetylcysteine
Hoestil
Hustengetränk, optipect
Hydrochloride, acetylcysteine
Ilube
Inpharzam brand OF acetylcysteine
Intra brand OF acetylcysteine
Jenacystein
Jenapharm
Klinge brand OF acetylcysteine
Krewel brand OF acetylcysteine
L-a-Acetamido-b-mercaptopropionate
L-a-Acetamido-b-mercaptopropionic acid
L-Acetylcysteine
L-alpha-Acetamido-beta-mercaptopropionate
L-alpha-Acetamido-beta-mercaptopropionic acid
Lantamed
Larylin nac
Lichtenstein brand OF acetylcysteine
Lindocetyl
Lindopharm brand OF acetylcysteine
Lysox
L-Α-acetamido-β-mercaptopropionate
L-Α-acetamido-β-mercaptopropionic acid
m Pectil
Mentopin acetylcystein
Mercaptate
Mercaptic acid
Mercapturic acid
Merck brand OF acetylcysteine
Monoammonium salt acetylcysteine
Monosodium salt acetylcysteine
m-Pectil
MPectil
Muciteran
muco Sanigen
Mucolysin
Mucomyst
Mucopect, dampo
Mucosil
MUCOSIL-10
MUCOSIL-20
Mucosol
Mucosolvin
N Acetyl L cysteine
N Acetylcysteine
NAC
NAC al
NAC zambon
NAC, bisolvon
N-Acetyl-3-mercaptoalanine
N-Acetylcysteine
N-Acety-L-cysteine
N-Acetyl-L-(+)-cysteine
N-Acetyl-L-cysteine
NSC-111180
Oberlin brand OF acetylcysteine
Optipect hustengetränk
ORONAC 600
PARVOLEX
Pfleger brand OF acetylcysteine
Pharbita brand OF acetylcysteine
Produpharm lappe brand OF acetylcysteine
RESPI-NAC
Roberts brand OF acetylcysteine
Roche nicholas brand OF acetylcysteine
Sanigen, muco
Siccoral
Siran
Sodium 2-acetamido-3-mercaptopropionate
Sodium, acetylcysteine
Solmucol
Temmler brand OF acetylcysteine
Teva brand OF acetylcysteine
Thiemann brand OF acetylcysteine
Trommsdorff brand OF acetylcysteine
UPSA brand OF acetylcysteine
Whitehall brand OF acetylcysteine
YOURNAC
Zambon brand OF acetylcysteine
Zambon, nac
Zinc, acetylcysteine
Zyma brand OF acetylcysteine
|
|
2 |
|
Cetirizine |
Approved |
Phase 4 |
|
83881-51-0 |
2678 |
Synonyms:
(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid
(2-{4-[(4-CHLOROPHENYL)(PHENYL)METHYL]PIPERAZIN-1-YL}ETHOXY)ACETIC ACID
AC-170
Alerlisin
Aliud brand OF cetirizine dihydrochloride
Alpharma brand OF cetirizine dihydrochloride
AWD.pharma brand OF cetirizine dihydrochloride
Azupharma brand OF cetirizine dihydrochloride
Basics brand OF cetirizine dihydrochloride
Benaday
Cetalerg
Ceterifug
Ceti tad
Cetiderm
Cetidura
Cetil von CT
CetiLich
Ceti-puren
Cetirigamma
Cetirizin
Cetirizin al
Cetirizin azu
Cetirizin basics
Cetirizina
CETIRIZINE
Cetirizine dihydrochloride
Cetirizine hydrochloride
Cetirizinum
Cetirlan
|
CT-Arzneimittel brand OF cetirizine dihydrochloride
Dermapharm brand OF cetirizine dihydrochloride
Dihydrochloride, cetirizine
glaxo Wellcome brand OF cetirizine dihydrochloride
Humex
Krewel brand OF cetirizine dihydrochloride
Lacer brand OF cetirizine dihydrochloride
Lichtenstein brand OF cetirizine dihydrochloride
Menarini brand OF cetirizine dihydrochloride
Merck dura brand OF cetirizine dihydrochloride
Pfizer brand OF cetirizine dihydrochloride
Pfizer consumer healthcare brand OF cetirizine dihydrochloride
Reactine
Reactine®|Zyrtec®
Rodleben brand OF cetirizine
Sanofi synthelabo brand OF cetirizine dihydrochloride
TAD brand OF cetirizine dihydrochloride
UCB brand OF cetirizine dihydrochloride
UCB pharma brand OF cetirizine dihydrochloride
United drug brand OF cetirizine dihydrochloride
Virlix
Voltric
Wolff brand OF cetirizine dihydrochloride
Wörwag brand OF cetirizine dihydrochloride
Zetir
Zirtek
Zyrlex
Zyrtec
|
|
3 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
4 |
|
Cysteine |
Approved, Nutraceutical |
Phase 4 |
|
52-90-4 |
594 5862 |
Synonyms:
(+)-2-AMINO-3-MERCAPTOPROPIONIC ACID
(2R)-2-AMINO-3-MERCAPTOPROPANOATE
(2R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(2R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(2R)-2-AMINO-3-SULFANYLPROPANOATE
(2R)-2-AMINO-3-SULFANYLPROPANOIC ACID
(2R)-2-AMINO-3-SULFANYL-PROPANOIC ACID
(2R)-2-Amino-3-sulphanylpropanoate
(2R)-2-Amino-3-sulphanylpropanoic acid
(R)-(+)-CYSTEINE
(R)-2-AMINO-3-MERCAPTOPROPANOATE
(R)-2-AMINO-3-MERCAPTO-PROPANOATE
(R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(R)-CYSTEINE
2-Amino-3-mercaptopropanoate
2-Amino-3-mercaptopropanoic acid
2-Amino-3-mercaptopropionate
2-Amino-3-mercaptopropionic acid
2-Amino-3-sulfanylpropanoate
2-Amino-3-sulfanylpropanoic acid
2-Amino-3-sulphanylpropanoate
2-Amino-3-sulphanylpropanoic acid
3-MERCAPTO-L-ALANINE
ACETYLCYSTEINE
ALPHA-AMINO-BETA-THIOLPROPIONIC ACID
BETA-MERCAPTOALANINE
B-MERCAPTOALANINE
C
CARBOCYSTEINE
Cisteina
|
CISTEINUM
Cys
Cystein
Cysteine
CYSTEINE HCL
Cysteine hydrochloride
CYSTEINUM
E 920
E920
E-920
E921
Ecolan
FREE CYSTEINE
Half cystine
Half-cystine
Hcys
L Cysteine
L-(+)-CYSTEINE
L-2-AMINO-3-MERCAPTOPROPANOATE
L-2-AMINO-3-MERCAPTOPROPANOIC ACID
L-2-Amino-3-mercaptopropionate
L-2-AMINO-3-MERCAPTOPROPIONIC ACID
L-CYS
L-CYSTEIN
L-Cysteine
L-ZYSTEIN
POLYCYSTEINE
THIOSERINE
Zinc cysteinate
Zystein
|
|
5 |
|
N-monoacetylcystine |
|
Phase 4 |
|
|
|
6 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
7 |
|
Histamine phosphate |
|
Phase 4 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
8 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 4 |
|
|
|
9 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
10 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
11 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
12 |
|
Dutasteride |
Approved, Investigational |
Phase 3 |
|
164656-23-9 |
6918296 |
Synonyms:
(5a,17b)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5Α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-N-(2,5-Bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
745, GG
a,a,a,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5a-androst-1-ene-17b-carboxy-2',5'-xylidide
alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
|
Avodart
Dutasterida
DUTASTERIDE
GG-745
GI-198745
Α,α,α,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide
α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide
|
|
13 |
|
Nitric Oxide |
Approved |
Phase 1, Phase 2 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
EDRF
Endogenous nitrate vasodilator
Endothelium-derived nitric oxide
Endothelium-derived relaxing factor
HYDROXYAMINE
INOmax
INOmax®|nitric oxide|nitrogen monoxide
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, nitrogen
Monoxido de nitrogeno
Monóxido de nitrógeno
Monoxyde d'azote
Nitrate vasodilator, endogenous
NITRIC OXIDE
Nitric oxide, endothelium derived
Nitric oxide, endothelium-derived
Nitrogen monooxide
|
Nitrogen monoxide
Nitrogen oxide
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM-11771
Oxide, nitric
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
Oxido nitrico
óxido nítrico
Oxyde azotique
Oxyde nitrique
Stickstoff(II)-oxid
Stickstoffmonoxid
Vasodilator, endogenous nitrate
|
|
14 |
|
Bimatoprost |
Approved, Investigational |
Phase 2 |
|
155206-00-1 |
5311027 |
Synonyms:
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
AGN 192024
AGN 192024|LS-181817|Lumigan®
AGN-192024
BIMATOPROST
|
Bimatoprostum
Latisse
LS-181817
Lumigan
|
|
15 |
|
Acetylcholine |
Approved, Investigational |
Phase 2 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
16 |
|
Valproic acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
17 |
|
Dinoprost tromethamine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
38562-01-5 |
|
Synonyms:
DINOPROST TROMETAMOL
DINOPROST TROMETHAMINE
LUTALYSE
PGF2A
PGF2A THAM
PGF2alpha THAM
PGF2-alpha THAM
|
PGF2ALPHA-THAM
PROSTAGLANDIN F 2 ALPHA
Prostaglandin F2a tromethamine
Prostaglandin F2alpha tham
Prostaglandin F2-alpha THAM
PROSTIN F2 ALPHA
U-14583E
|
|
18 |
|
Dinoprost |
Approved, Investigational |
Phase 1, Phase 2 |
|
551-11-1 |
5283078 5280363 |
Synonyms:
(+)-Prostaglandin F2a
(5Z,13E)-(15S)-9-alpha,11-alpha,15-Trihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9-alpha,11-alpha,15-Trihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-9a,11a,15-Trihydroxyprosta-5,13-dien-1-Oate
(5Z,13E,15S)-9a,11a,15-Trihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oic acid
(9alpha,11alpha,15)-Trihydroxyprosta-(5Z,13E)-dien-1-Oate
(9alpha,11alpha,15)-Trihydroxyprosta-(5Z,13E)-dien-1-Oic acid
7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate
7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid
9,11,15-Trihydroxy-(5Z,9a,11a,13E,15S)-prosta-5,13-dien-1-Oate
9,11,15-Trihydroxy-(5Z,9a,11a,13E,15S)-prosta-5,13-dien-1-Oic acid
9,11,15-Trihydroxyprosta-5Z,13E-dien-1-Oate
9,11,15-Trihydroxyprosta-5Z,13E-dien-1-Oic acid
9a,11a,15(S)-Trihydroxy-5-cis-13-trans-prostadienoate
9a,11a,15(S)-Trihydroxy-5-cis-13-trans-prostadienoic acid
9a,11a-PGF2
9a,11a-PGF2a
9alpha,11beta PGF2
9alpha,11beta-PGF2
alpha, PGF2
Amoglandin
Cyclosin
Dinifertin
|
DINOPROST
dinoprosta
Enzaprost
Enzaprost F
Estrofan
F2 alpha, Prostaglandin
F2a Isoprostane
F2alpha, Prostaglandin
Glandin N
L-PGF2-alpha
L-Prostaglandin F2-alpha
Panacelan
PGF2
PGF2 alpha
PGF2a
PGF2alpha
prostaglandin F<sub>2α</sub>
Prostaglandin F2
Prostaglandin F2 alpha
Prostaglandin F2alpha
Prostamate
Prostarmon F
Prostin F 2 alpha
Protamodin
U-14583
|
|
19 |
|
Ascorbic acid |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
20 |
|
Maleic acid |
Experimental, Investigational |
Phase 1, Phase 2 |
|
110-16-7, 110-17-8 |
444266 444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
Allomaleate
Allomaleic acid
Boletate
Boletic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
e297
FC 33
Fumarate
Fumaric acid
Fumaricum acidum
Fumarsaeure
|
Fumarsäure
Furamag
H2Male
Hydrogen maleate
Kyselina maleinova
Lichenate
Lichenic acid
MAE
Mafusol
Maleate
MALEIC ACID
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
|
|
21 |
|
Ammonium trichloro(dioxoethylene-O,O'-)tellurate |
|
Phase 2 |
|
|
|
22 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
23 |
|
Radiation-Protective Agents |
|
Phase 2 |
|
|
|
24 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
25 |
|
Reverse Transcriptase Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
27 |
|
Protective Agents |
|
Phase 2 |
|
|
|
28 |
|
Bronchodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Anti-Asthmatic Agents |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Endothelium-Dependent Relaxing Factors |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Respiratory System Agents |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Antioxidants |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
34 |
|
Androgens |
|
Phase 2 |
|
|
|
35 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
36 |
|
HIV Protease Inhibitors |
|
Phase 2 |
|
|
|
37 |
|
Proteasome Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
protease inhibitors |
|
Phase 2 |
|
|
|
Synonyms:
|
39 |
|
abobotulinumtoxinA |
|
Phase 2 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
40 |
|
Botulinum Toxins, Type A |
|
Phase 2 |
|
|
|
41 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
42 |
|
Ophthalmic Solutions |
|
Phase 2 |
|
|
|
43 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
44 |
|
Anticonvulsants |
|
Phase 2 |
|
|
|
45 |
|
Botulinum Toxins |
|
Phase 2 |
|
|
|
46 |
|
incobotulinumtoxinA |
|
Phase 2 |
|
|
|
Synonyms:
|
47 |
|
Anesthetics |
|
Phase 1 |
|
|
|
48 |
|
Androgen Receptor Antagonists |
|
Phase 1 |
|
|
|
49 |
|
Roxithromycin |
Approved, Investigational, Withdrawn |
|
|
80214-83-1 |
6915744 |
Synonyms:
(9E)-ERYTHROMYCIN 9-(O-((2-METHOXYETHOXY)METHYL)OXIME)
1a Brand OF roxithromycin
9-[O-(2-Methoxyethoxymethyl)-oxime] OF erythromycin
Alpharma brand OF roxithromycin
Aventis brand OF roxithromycin
Basics brand OF roxithromycin
Betapharm brand OF roxithromycin
Biaxsig
Claramid
CT-Arzneimittel brand OF roxithromycin
Faes brand OF roxithromycin
Grünenthal brand OF roxithromycin
Hexal brand OF roxithromycin
Hoechst brand OF roxithromycin
Infectopharm brand OF roxithromycin
Infectoroxit
Juta brand OF roxithromycin
Knoll brand OF roxithromycin
Lichtenstein brand OF roxithromycin
Macrosil
Medeva brand OF roxithromycin
Merck dura brand OF roxithromycin
MIP brand OF roxithromycin
MTW Brand OF roxithromycin
MTW-Roxithromycin
Pfizer brand OF roxithromycin
Rotesan
Rotramin
|
Roxi 1a pharma
Roxi basics
Roxi tad
Roxi von CT
Roxibeta
Roxidura
Roxigamma
Roxigrün
Roxihexal
Roxi-paed 1a pharma
Roxi-puren
Roxi-Q
Roxi-saar
Roxithro-lich
ROXITHROMYCIN
Roxithromycin hexal brand
ROXITHROMYCINE
ROXITHROMYCINUM
ROXITROMICINA
Roxi-wolff
RU-28965
RU-965
Rulid
Rulide
Sigma brand OF roxithromycin
TAD brand OF roxithromycin
Wolff brand OF roxithromycin
Wörwag brand OF roxithromycin
|
|
50 |
|
Cyproterone acetate |
Approved, Investigational |
|
|
427-51-0 |
9880 |
Synonyms:
ANDROCUR
ANDROCUR 10
Androcur®|Cyprostat®|SH-714
CYPROSTAT
CYPROSTAT®
CYPROTERONE
|
CYPROTERONE 17-O-ACETATE
CYPROTERONE ACETATE
DIANE
NSC-81430
SH-714
|
|
Interventional clinical trials:
(show top 50)
(show all 149)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial |
Unknown status |
NCT03388840 |
Phase 4 |
|
2 |
Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men |
Unknown status |
NCT04209803 |
Phase 4 |
Minoxidil 5% topically and oral NAC 600 mg |
3 |
Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia |
Unknown status |
NCT04293822 |
Phase 4 |
Cetirizine;Minoxidil |
4 |
Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial |
Unknown status |
NCT02999737 |
Phase 4 |
|
5 |
Minoxidil in Treatment of Androgenetic Alopecia |
Completed |
NCT04090801 |
Phase 4 |
Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone |
6 |
The Use of Hydradermabrasion in the Scalp to Improve Scalp Health and Improve Outcomes in Androgenetic Alopecia |
Recruiting |
NCT05426629 |
Phase 4 |
|
7 |
The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia |
Withdrawn |
NCT02483195 |
Phase 4 |
5% Minoxidil;200mg Spironolactone;5mg Finasteride |
8 |
BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA |
Unknown status |
NCT01655108 |
Phase 3 |
Minoxidil;Saline |
9 |
A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) |
Completed |
NCT04019795 |
Phase 3 |
|
10 |
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia |
Completed |
NCT03742518 |
Phase 2, Phase 3 |
Topical SM04554 solution;Topical vehicle solution |
11 |
Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study |
Completed |
NCT03753113 |
Phase 3 |
Topical Herbal Solution;Topical Minoxidil 5% |
12 |
A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia |
Completed |
NCT02014584 |
Phase 3 |
Dutasteride;Placebo |
13 |
An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) |
Completed |
NCT00441116 |
Phase 3 |
Dutasteride 0.5mg oral tablets |
14 |
Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia |
Completed |
NCT01831791 |
Phase 3 |
Dutasteride 0.5 mg |
15 |
A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia |
Completed |
NCT00396175 |
Phase 3 |
MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks |
16 |
A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males |
Completed |
NCT00151515 |
Phase 3 |
minoxidil |
17 |
Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume |
Completed |
NCT00958750 |
Phase 3 |
minoxidil |
18 |
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial |
Completed |
NCT05296863 |
Phase 3 |
|
19 |
A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) |
Completed |
NCT01145625 |
Phase 3 |
5% Minoxidil;2% Minoxidil |
20 |
A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia |
Completed |
NCT01231607 |
Phase 3 |
1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo |
21 |
A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) |
Completed |
NCT01226459 |
Phase 3 |
5% Minoxidil Topical Foam;Vehicle Topical Foam |
22 |
Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study |
Completed |
NCT01391156 |
Phase 3 |
3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion |
23 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia |
Recruiting |
NCT04825561 |
Phase 3 |
AD-208;AD-2081;placebo of AD-208;placebo of AD-2081 |
24 |
The Role of Cetirizine in Androgenetic Alopecia in Females |
Active, not recruiting |
NCT04481412 |
Phase 2, Phase 3 |
Topical cetirizine;Placebo;Topical minoxidil |
25 |
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA) |
Active, not recruiting |
NCT05135468 |
Phase 3 |
CU-40102 Spray |
26 |
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. |
Not yet recruiting |
NCT04594018 |
Phase 3 |
Finlândia Association + finasteride placebo;Minoxidil + finasteride |
27 |
A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks |
Not yet recruiting |
NCT04721548 |
Phase 3 |
Minoxidil Topical Foam;Placebo |
28 |
Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women |
Unknown status |
NCT00418249 |
Phase 2 |
AS101 |
29 |
A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men |
Unknown status |
NCT00471510 |
Phase 2 |
tetrapeptide aldehyde proteasome inhibitor (NEOSH101) |
30 |
A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradomeâ„¢ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia |
Unknown status |
NCT02528552 |
Phase 2 |
|
31 |
A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) |
Unknown status |
NCT01643629 |
Phase 1, Phase 2 |
|
32 |
A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant |
Unknown status |
NCT01644422 |
Phase 1, Phase 2 |
|
33 |
Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia |
Unknown status |
NCT01347957 |
Phase 1, Phase 2 |
|
34 |
The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial |
Unknown status |
NCT01501617 |
Phase 1, Phase 2 |
|
35 |
A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers |
Completed |
NCT03467412 |
Phase 2 |
FOL-005;Placebo |
36 |
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) |
Completed |
NCT01904721 |
Phase 2 |
Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle |
37 |
A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women |
Completed |
NCT03488108 |
Phase 1, Phase 2 |
Minoxidil Foam |
38 |
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia |
Completed |
NCT01325337 |
Phase 2 |
bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution |
39 |
Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
Completed |
NCT02150187 |
Phase 2 |
|
40 |
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) |
Completed |
NCT02275351 |
Phase 2 |
SM04554;Vehicle |
41 |
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males |
Completed |
NCT02781311 |
Phase 2 |
Setipiprant;Placebo;Finasteride |
42 |
A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia |
Completed |
NCT02280603 |
Phase 1, Phase 2 |
DA-4001C;5% minoxidil |
43 |
A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) |
Completed |
NCT02279823 |
Phase 2 |
CB-03-01 solution;Minoxidil Solution 5%;Placebo solution |
44 |
A Randomized, Double-blind, Vehicle-controlled, Dose-finding Multi-center, Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers With Androgenetic Alopecia |
Completed |
NCT04774874 |
Phase 2 |
Topical formulation |
45 |
A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men |
Completed |
NCT00418730 |
Phase 2 |
tetrapeptide aldehyde proteasome inhibitor (NEOSH101) |
46 |
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing |
Completed |
NCT02503137 |
Phase 2 |
Topical SM04554 solution;Topical Vehicle solution |
47 |
A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia |
Completed |
NCT00965640 |
Phase 2 |
Botulinum Toxin - A injections |
48 |
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
Completed |
NCT03495817 |
Phase 2 |
ATI-50002 |
49 |
Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks |
Completed |
NCT01319370 |
Phase 2 |
Minoxidil;vehicle of 5% Minoxidil topical foam |
50 |
Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. |
Completed |
NCT01286649 |
Phase 1, Phase 2 |
|
|